{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T08:41:36Z","timestamp":1765960896581},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Menarini Hellas"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1186\/s12913-015-1228-y","type":"journal-article","created":{"date-parts":[[2015,12,18]],"date-time":"2015-12-18T05:01:25Z","timestamp":1450414885000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Greece: a cost-utility study"],"prefix":"10.1186","volume":"15","author":[{"given":"Georgia","family":"Kourlaba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charalambos","family":"Vlachopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Parissis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Kanakakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Gourzoulidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikos","family":"Maniadakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,12,18]]},"reference":[{"key":"1228_CR1","volume-title":"NICE clinical guideline 126","author":"National Institute for Health and Care Excellence (NICE)","year":"2012","unstructured":"National Institute for Health and Care Excellence (NICE). Management of stable angina. In: NICE clinical guideline 126. 2012. https:\/\/www.nice.org.uk\/guidance\/cg126\/resources\/stable-angina-management-35109453262021 . Accessed 15, October 2015."},{"issue":"11","key":"1228_CR2","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/eurheartj\/ehl001","volume":"27","author":"K Fox","year":"2006","unstructured":"Fox K, Garcia MA, Ardissino D, Buszman P, Camici PG, Crea F, et al. Guidelines on the management of stable angina pectoris: executive summary: the task force on the management of stable angina pectoris of the European Society of Cardiology. Eur Heart J. 2006;27(11):1341\u201381.","journal-title":"Eur Heart J"},{"issue":"1","key":"1228_CR3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1161\/01.CIR.0000020688.24874.90","volume":"106","author":"JA Spertus","year":"2002","unstructured":"Spertus JA, Jones P, McDonell M, Fan V, Fihn SD. Health status predicts long-term outcome in outpatients with coronary disease. Circulation. 2002;106(1):43\u20139.","journal-title":"Circulation"},{"issue":"4","key":"1228_CR4","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1161\/CIRCOUTCOMES.108.829523","volume":"2","author":"SV Arnold","year":"2009","unstructured":"Arnold SV, Morrow DA, Lei Y, Cohen DJ, Mahoney EM, Braunwald E, et al. Economic impact of angina after an acute coronary syndrome: insights from the MERLIN-TIMI 36 trial. Circ Cardiovasc Qual Outcomes. 2009;2(4):344\u201353.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"8","key":"1228_CR5","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1136\/heart.89.8.848","volume":"89","author":"S Stewart","year":"2003","unstructured":"Stewart S, Murphy NF, Walker A, McGuire A, McMurray JJ. The current cost of angina pectoris to the National Health Service in the UK. Heart. 2003;89(8):848\u201353.","journal-title":"Heart"},{"issue":"6","key":"1228_CR6","first-page":"353","volume":"4","author":"J Kempf","year":"2011","unstructured":"Kempf J, Buysman E, Brixner D. Health resource utilization and direct costs associated with angina for patients with coronary artery disease in a US managed care setting. Am Health Drug Benefits. 2011;4(6):353\u201361.","journal-title":"Am Health Drug Benefits"},{"issue":"11 Suppl","key":"1228_CR7","first-page":"S347","volume":"10","author":"MW Reynolds","year":"2004","unstructured":"Reynolds MW, Frame D, Scheye R, Rose ME, George S, Watson JB, et al. A systematic review of the economic burden of chronic angina. Am J Manag Care. 2004;10(11 Suppl):S347\u201357.","journal-title":"Am J Manag Care"},{"issue":"4","key":"1228_CR8","first-page":"272","volume":"55","author":"G Andrikopoulos","year":"2014","unstructured":"Andrikopoulos G, Parissis J, Filippatos G, Nikolaou M, Pantos K, Voudris V, et al. Medical management of stable angina. Hellenic J Cardiol. 2014;55(4):272\u201380.","journal-title":"Hellenic J Cardiol"},{"issue":"10","key":"1228_CR9","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.acvd.2011.08.001","volume":"104","author":"JL Gayet","year":"2011","unstructured":"Gayet JL, Paganelli F, Cohen-Solal A. Update on the medical treatment of stable angina. Arch Cardiovasc Dis. 2011;104(10):536\u201344.","journal-title":"Arch Cardiovasc Dis"},{"issue":"1","key":"1228_CR10","doi-asserted-by":"crossref","first-page":"63","DOI":"10.7861\/clinmedicine.13-1-63","volume":"13","author":"JM Tarkin","year":"2013","unstructured":"Tarkin JM, Kaski JC. Pharmacological treatment of chronic stable angina pectoris. Clin Med. 2013;13(1):63\u201370.","journal-title":"Clin Med"},{"issue":"15","key":"1228_CR11","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa070829","volume":"356","author":"WE Boden","year":"2007","unstructured":"Boden WE, O\u2019Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356(15):1503\u201316.","journal-title":"N Engl J Med"},{"issue":"1","key":"1228_CR12","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s40265-012-0005-z","volume":"73","author":"GM Keating","year":"2013","unstructured":"Keating GM. Ranolazine: a review of its use as add-on therapy in patients with chronic stable angina pectoris. Drugs. 2013;73(1):55\u201373.","journal-title":"Drugs"},{"issue":"6","key":"1228_CR13","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1161\/01.CIR.0000048143.25023.87","volume":"107","author":"JS Borer","year":"2003","unstructured":"Borer JS, Fox K, Jaillon P, Lerebours G, Ivabradine Investigators G. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation. 2003;107(6):817\u201323.","journal-title":"Circulation"},{"issue":"11","key":"1228_CR14","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.amjcard.2005.01.069","volume":"95","author":"BR Chaitman","year":"2005","unstructured":"Chaitman BR, Ivleva AY, Ujda M, Lenis JH, Toth C, Stieber DM, et al. Antianginal efficacy of omapatrilat in patients with chronic angina pectoris. Am J Cardiol. 2005;95(11):1283\u20139.","journal-title":"Am J Cardiol"},{"issue":"23","key":"1228_CR15","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/eurheartj\/ehi586","volume":"26","author":"JC Tardif","year":"2005","unstructured":"Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K, Investigators I. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J. 2005;26(23):2529\u201336.","journal-title":"Eur Heart J"},{"issue":"10","key":"1228_CR16","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/j.jacc.2005.07.047","volume":"46","author":"RM Vicari","year":"2005","unstructured":"Vicari RM, Chaitman B, Keefe D, Smith WB, Chrysant SG, Tonkon MJ, et al. Efficacy and safety of fasudil in patients with stable angina: a double-blind, placebo-controlled, phase 2 trial. J Am Coll Cardiol. 2005;46(10):1803\u201311.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1228_CR17","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jama.291.3.309","volume":"291","author":"BR Chaitman","year":"2004","unstructured":"Chaitman BR, Pepine CJ, Parker JO, Skopal J, Chumakova G, Kuch J, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004;291(3):309\u201316.","journal-title":"JAMA"},{"issue":"8","key":"1228_CR18","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.jacc.2003.11.045","volume":"43","author":"BR Chaitman","year":"2004","unstructured":"Chaitman BR, Skettino SL, Parker JO, Hanley P, Meluzin J, Kuch J, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004;43(8):1375\u201382.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"1228_CR19","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/00005344-200408000-00008","volume":"44","author":"Y Song","year":"2004","unstructured":"Song Y, Shryock JC, Wu L, Belardinelli L. Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes. J Cardiovasc Pharmacol. 2004;44(2):192\u20139.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"2","key":"1228_CR20","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1124\/jpet.104.066100","volume":"310","author":"L Wu","year":"2004","unstructured":"Wu L, Shryock JC, Song Y, Li Y, Antzelevitch C, Belardinelli L. Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome. J Pharmacol Exp Ther. 2004;310(2):599\u2013605.","journal-title":"J Pharmacol Exp Ther"},{"key":"1228_CR21","volume-title":"Ranexa: summary of product characteristics","author":"European Medicines Agency","year":"2008","unstructured":"European Medicines Agency. Ranexa: summary of product characteristics. 2008. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000805\/WC500045937.pdf . Accessed 13 October 2014."},{"issue":"3","key":"1228_CR22","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.jacc.2006.05.044","volume":"48","author":"PH Stone","year":"2006","unstructured":"Stone PH, Gratsiansky NA, Blokhin A, Huang IZ, Meng L, Investigators E. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol. 2006;48(3):566\u201375.","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"1228_CR23","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1001\/jama.297.16.1775","volume":"297","author":"DA Morrow","year":"2007","unstructured":"Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Murphy SA, Budaj A, Varshavsky S, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA. 2007;297(16):1775\u201383.","journal-title":"JAMA"},{"issue":"9","key":"1228_CR24","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s10198-013-0534-8","volume":"15","author":"A Hidalgo-Vega","year":"2013","unstructured":"Hidalgo-Vega A, Ramos-Goni JM, Villoro R. Cost-utility of ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Spain. Eur J Health Econ. 2013;15(9):917\u201325.","journal-title":"Eur J Health Econ"},{"issue":"2","key":"1228_CR25","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1161\/CIRCOUTCOMES.108.798009","volume":"1","author":"SV Arnold","year":"2008","unstructured":"Arnold SV, Morrow DA, Wang K, Lei Y, Mahoney EM, Scirica BM, et al. Effects of ranolazine on disease-specific health status and quality of life among patients with acute coronary syndromes: results from the MERLIN-TIMI 36 randomized trial. Circ Cardiovasc Qual Outcomes. 2008;1(2):107\u201315.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"4","key":"1228_CR26","doi-asserted-by":"crossref","first-page":"300","DOI":"10.18553\/jmcp.2005.11.4.300","volume":"11","author":"LR Etemad","year":"2005","unstructured":"Etemad LR, McCollam PL. Total first-year costs of acute coronary syndrome in a managed care setting. J Manag Care Pharm. 2005;11(4):300\u20136.","journal-title":"J Manag Care Pharm"},{"issue":"4","key":"1228_CR27","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s10198-005-0309-y","volume":"6","author":"L Longworth","year":"2005","unstructured":"Longworth L, Buxton MJ, Sculpher M, Smith DH. Estimating utility data from clinical indicators for patients with stable angina. Eur J Health Econ. 2005;6(4):347\u201353.","journal-title":"Eur J Health Econ"},{"issue":"3","key":"1228_CR28","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1093\/europace\/eus400","volume":"15","author":"E Karwatowska-Prokopczuk","year":"2013","unstructured":"Karwatowska-Prokopczuk E, Wang W, Cheng ML, Zeng D, Schwartz PJ, Belardinelli L. The risk of sudden cardiac death in patients with non-ST elevation acute coronary syndrome and prolonged QTc interval: effect of ranolazine. Europace. 2013;15(3):429\u201336.","journal-title":"Europace"},{"issue":"2","key":"1228_CR29","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0735-1097(94)00397-9","volume":"25","author":"JA Spertus","year":"1995","unstructured":"Spertus JA, Winder JA, Dewhurst TA, Deyo RA, Prodzinski J, McDonell M, et al. Development and evaluation of the Seattle angina questionnaire: a new functional status measure for coronary artery disease. J Am Coll Cardiol. 1995;25(2):333\u201341.","journal-title":"J Am Coll Cardiol"},{"key":"1228_CR30","volume-title":"Drug price bulletin 2014","author":"Greek Ministry of Health","year":"2014","unstructured":"Greek Ministry of Health. Drug price bulletin 2014. 2014. http:\/\/www.moh.gov.gr\/articles\/times-farmakwn\/deltia-timwn . Accessed 8 February 2015."},{"key":"1228_CR31","unstructured":"Greek Ministry of Health. Diagnostic related groups FEK 9468\/27-3-12. Athens. http:\/\/www.moh.gov.gr\/articles\/health\/domes-kai-draseis-gia-thn-ygeia\/kwdikopoihseis\/709-kleista-enopoihmena-noshlia-1 . Accessed 8 February 2015."},{"key":"1228_CR32","volume-title":"Choosing interventions that are cost effective (WHO-CHOICE): cost-effectiveness thresholds","author":"WHO","year":"2013","unstructured":"WHO. Choosing interventions that are cost effective (WHO-CHOICE): cost-effectiveness thresholds. 2013. http:\/\/www.who.int\/choice\/en\/ . Accessed 28 February 2015."},{"key":"1228_CR33","volume-title":"World economic outlook database","author":"International Monetary Fund","year":"2013","unstructured":"International Monetary Fund. World economic outlook database. 2013. http:\/\/www.imf.org\/external\/pubs\/ft\/weo\/2012\/02\/weodata\/index.aspx . Accessed 15 February 2015."},{"key":"1228_CR34","volume-title":"Handbooks in health economic evaluation","author":"A Briggs","year":"2006","unstructured":"Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. In: Gray A, Briggs A, editors. Handbooks in health economic evaluation. 2006."},{"issue":"23","key":"1228_CR35","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1002\/1097-0258(20001215)19:23<3219::AID-SIM623>3.0.CO;2-P","volume":"19","author":"JA Barber","year":"2000","unstructured":"Barber JA, Thompson SG. Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. Stat Med. 2000;19(23):3219\u201336.","journal-title":"Stat Med"},{"issue":"8","key":"1228_CR36","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.amjcard.2014.01.407","volume":"113","author":"CG Kohn","year":"2014","unstructured":"Kohn CG, Parker MW, Limone BL, Coleman CI. Cost-effectiveness of ranolazine added to standard-of-care treatment in patients with chronic stable angina pectoris. Am J Cardiol. 2014;113(8):1306\u201311.","journal-title":"Am J Cardiol"},{"key":"1228_CR37","doi-asserted-by":"crossref","first-page":"A323","DOI":"10.1016\/j.jval.2014.08.1429","volume":"17","author":"SG Gorokhova","year":"2014","unstructured":"Gorokhova SG. ea. Cost-effectiveeness of ranolazIne for the treatment of angIna Pectoris in RussIa. Value Health. 2014;17:A323\u2013686.","journal-title":"Value Health"},{"issue":"6","key":"1228_CR38","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.clinthera.2012.04.025","volume":"34","author":"CE Phelps","year":"2012","unstructured":"Phelps CE, Buysman EK, Gomez RG. Costs and clinical outcomes associated with use of ranolazine for treatment of angina. Clin Ther. 2012;34(6):1395\u2013407.e4.","journal-title":"Clin Ther"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-015-1228-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T19:10:47Z","timestamp":1653851447000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.biomedcentral.com\/1472-6963\/15\/566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["1228"],"URL":"https:\/\/doi.org\/10.1186\/s12913-015-1228-y","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6]]},"article-number":"566"}}